Full-Time

Director of Quality Assurance

Clinical

Caribou Biosciences

Caribou Biosciences

51-200 employees

Develops allogeneic CRISPR CAR-T therapies

Compensation Overview

$220k - $235k/yr

+ Bonus + Equity

No H1B Sponsorship

Berkeley, CA, USA

Hybrid

Travel up to 25-30% based on business needs.

US Citizenship, US Top Secret Clearance, Canada Citizenship, Canada Top Secret Clearance, UK Citizenship, UK Top Secret Clearance Required

Category
QA & Testing (1)
Required Skills
Risk Management
Google Cloud Platform
Requirements
  • Undergraduate or graduate degree in Biological Sciences, Chemistry, or related Science discipline with at least 15 years of experience in clinical quality assurance (GCP, GLP and PV) in cell & gene therapy/biotechnology and/or pharmaceutical industry.
  • Experience working in biologics is strongly preferred.
  • Subject Matter Expert (SME) working knowledge on current interpretation/implementation of United States Code of Federal Regulations, ICH Guidelines and other local government regulatory requirements governing clinical research.
  • Proven track record in developing and implementing quality systems and processes in a clinical setting.
  • Expertise in creating and executing audit plans outlining all service providers (vendor) audits, clinical investigator site audits, CSV audits and process audits.
  • Advanced knowledge of Quality Assurance principles, concepts, industry practices, and standards.
  • Prior GLP experience with quality oversight and auditing studies/vendors (preferred).
  • Excellent verbal and written communication skills, ability to lead cross-functional teams and independently prioritize work, manage multiple projects while maintaining quality and being an advocate for quality and regulatory compliance.
  • The position requires a highly diplomatic, and tactful individual with excellent critical reasoning skills.
  • Conscientiously detail-oriented and organized, impeccable attention to data review.
  • Ability to deal with ambiguity and use expertise and skills to contribute to the development of company objectives and principles, and to achieve goals in creative and effective ways.
  • Must be flexible and able to multi-task, prioritize, meet deadlines in a fast-paced environment, and be adaptable to setbacks.
  • Detail-oriented mindset with a proactive approach to problem-solving and decision-making.
  • Certification in quality assurance (e.g., Certified Quality Auditor) and/or GCP (e.g., Certified Clinical Research Professional) is desirable.
  • Ability to travel up to 25-30% based on business needs.
Responsibilities
  • Compliance Oversight: Ensure that all clinical trial activities comply with guidelines and international regulations (e.g., ICH-GCP and ICH-PV), and applicable laws.
  • Documentation Review: Conduct thorough reviews of study-related documentation, including protocols, investigator brochures, informed consent forms, and CSRs, to verify compliance with GCP requirements.
  • Provide Clinical Quality Assurance (GCP) strategic and technical leadership and Subject Matter Expertise (SME) to clinical study teams; Partner with the teams to effect appropriate and timely documentation of quality event management, including CAPA plans in support of product pipeline.
  • Plan and oversee activities in support of regulatory submissions and inspections; Lead GCP Inspection Readiness efforts, ensure implementation and prepare internal and external teams for Pre-Approval Inspections (PAI).
  • Implement, monitor, and promote best practices of all Quality Assurance Systems to ensure compliance with relevant FDA, EU and ROW regulations/directives/requirements and ICH guidelines.
  • Quality Management System (QMS): Maintain and enhance Caribou’s QMS by implementing processes and procedures that ensure consistent adherence to GCP, GLP and PV standards throughout the clinical trial lifecycle.
  • Develop and implement the appropriate suite of Standard Operating Procedures (SOPs), quality manuals, policies, and other related quality documents. Ensure that these systems are effectively communicated, understood, and followed by relevant stakeholders.
  • Create and implement clinical quality risk management strategies to identify, assess, and mitigate risks associated with clinical development and operations. This involves conducting risk assessments, developing risk mitigation plans, and overseeing their implementation.
  • Build training and approve curricula based on the key elements of the Quality System; Provide leadership and oversight for training programs related to pre-clinical, clinical and PV. Ensure that employees and relevant stakeholders receive appropriate training on quality standards, regulations, and procedures.
  • Establish and monitor quality metrics and key performance indicators for the effectiveness of pre-clinical, clinical, and PV quality assurance activities. Prepare routine reports and presentations for senior/executive management review highlighting quality performance, trends, and areas for improvement. Assist with tracking compliance audit trends and present to management.
  • Collaborate with cross-functional teams, including pre-clinical, clinical operations, regulatory affairs, pharmacovigilance, and other relevant departments, to ensure alignment and integration of quality assurance activities. Build and maintain effective relationships with internal and external stakeholders, including regulatory agencies and service providers.
  • Perform internal and external audits to ensure stakeholder system compliance with existing policies and procedures, and requirements, standards, and guidelines.
  • Lead and/or manage additional Quality Assurance (GxP) initiatives or programs as business needs evolve.
Desired Qualifications
  • Certification in quality assurance (e.g., Certified Quality Auditor) and/or GCP (e.g., Certified Clinical Research Professional) is desirable.
  • Travel availability up to 25-30%.

Caribou Biosciences develops allogeneic CAR-T cell therapies using a CRISPR-based chRDNA platform (Cas9 and Cas12a) to create precise genome edits. Its lead approach centers on off-the-shelf, armored CAR-T cells designed to persist longer and resist exhaustion, including PD-1 knockout, enabling rapid access for patients. The company advances wholly-owned programs and collaborates with pharma partners, such as AbbVie, to push its therapies through clinical development. Its goal is to bring regulated, off-the-shelf CAR-T therapies to patients with hematologic cancers and autoimmune diseases and to reach commercialization, supported by funding through at least 2027.

Company Size

51-200

Company Stage

IPO

Headquarters

Berkeley, California

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • CB-011 receives FDA RMAT designation on March 31, 2026.
  • $10 million revenue from 2024 licensing deals fuels pipeline.
  • Capital funds operations through second half of 2027.

What critics are saying

  • CRISPR Therapeutics' CTX112 achieves 85% ORR, surpassing CB-010's 60%.
  • Allogene's ALLO-501A gains FDA approval by Q2 2026, seizing 40% market.
  • Quarterly $120M cash burn exhausts funds by Q1 2027.

What makes Caribou Biosciences unique

  • chRDNA platform uses hybrid RNA-DNA guides for superior CRISPR specificity.
  • Cas12a and Cas9 technologies enable precise allogeneic CAR-T edits.
  • Founders include Nobel laureate Jennifer Doudna and Rachel Haurwitz.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Caribou Biosciences who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Tuition Reimbursement

Generous paid vacation time

Comprehensive compensation package

ESPP

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

5%
TipRanks
Jan 2nd, 2025
Caribou Biosciences Appoints New CFO Amid Clinical Advancements

Caribou Biosciences announced the appointment of Sri Ryali as Chief Financial Officer, effective January 2, 2025.

TechBullion
Sep 10th, 2024
Vir Biotechnology Names Jason O'Byrne as Chief Financial Officer

Mr. O'Byrne joins Vir from Caribou Biosciences, Inc., where he served as CFO, leading the finance, investor relations, corporate communications, IT, procurement, and operations functions as the company advanced its pipeline of clinical-stage cell therapies in oncology and autoimmune disease.

Stock Titan
Aug 12th, 2024
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

Caribou Biosciences (CRBU) has appointed Dr. Tina Albertson as its new Chief Medical Officer.

Endpoints News
Jul 17th, 2024
Caribou to slash preclinical allogeneic CAR-NK work, lay off 12% of staff

Caribou Biosciences is cutting its CAR-NK research and laying off 21 employees, or 12% of its staff, the company announced Tuesday.

Stock Titan
Jul 9th, 2024
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

Caribou Biosciences announces appointment of Terri Laufer, MD, to its scientific advisory board.